3 news items
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
KPTI
1 Jun 24
.2 Since 2000, the incidence of new cases and deaths from endometrial cancer have risen.3 Risk
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI
8 May 24
%.The most common adverse reactions (incidence ≥20%) in patients with DLBCL, excluding laboratory abnormalities
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
KPTI
24 Apr 24
reactions (incidence ≥20%) in patients with DLBCL, excluding laboratory abnormalities, are fatigue, nausea, diarrhea, appetite decrease, weight decrease
- Prev
- 1
- Next